Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Aldometanib (LXY-05-029) 是一种具有口服活性的醛缩酶抑制剂，可以阻止FBP 与v-ATPase 相关的醛缩酶结合，并激活溶酶体 AMPK 。Aldometanib 可用于代谢稳态的研究。
| 产品描述 | Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK. Aldometanib can be used for the research of metabolic homeostasis [1]. |
| 体外活性 | Aldometanib (0-1000 nM; 2 h) activates AMPK through preventing aldolase from binding to FBP to engender a pseudo-starvation signal [1]. Western Blot Analysis [1] Cell Line: Mouse primary hepatocytes, MEFs cells Concentration: 0-1000 nM Incubation Time: 2 h Result: Activated AMPK in mouse embryonic fibroblasts (MEFs) and mouse primary hepatocytes cells. Immunofluorescence [1] Cell Line: MEFs cells Concentration: 5 nM Incubation Time: 2 h Result: Inhibited TRPVs and induces AXIN lysosomal translocation. |
| 体内活性 | Aldometanib (oral; 0-10 mpk) lowers blood glucose in lean mice [1]. Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice [1]. Aldometanib alleviates fatty liver and nonalcoholic steatohepatitis [1]. Aldometanib (oral; 2mpk; twice-daily; for a month) alleviates liver fibrosis in NASH mice [1]. Aldometanib (oral; 0-50 μM; 0-50 days) extends lifespan in C. elegans via the lysosomal pathway [1]. Animal Model: Lean mice [1] Dosage: 0-10 mpk Administration: Oral Result: Decreased fasting blood glucose and improved glucose tolerance, promoted muscular TBC1D1 phosphorylation and glucose uptake. Animal Model: Obese hyperglycaemic mice [1] Dosage: 2-10 mpk Administration: Oral, twice daily, for a week Result: Decreased blood glucose, lowered blood glucose in a muscular AMPK-dependent manner reduced hepatic TAG, improved insulin sensitivity, increased glucose disposal rates, inhibited TAG synthesis in liver and primary hepatocytes, decreased fat mass. Animal Model: NASH mice [1] Dosage: 2 mpk Administration: Oral, twice-daily, for a month Result: Decreased histological scores used to describe the features of NASH, reduced apoptosis rate of hepatic cells, inhibited inflammatory responses in the liver of NASH mice and improved glucose tolerance of NASH mice. Animal Model: C. elegans [1] Dosage: 0-50 μM Administration: Oral, 0-50 days Result: Promoted oxidative stress resistance and mitochondrial functions in C. elegans. Animal Model: C57BL/6 mice [1] Dosage: 100 μg/mL Administration: Oral Result: Extended lifespan, elevated NAD ＋ levels and mitochondrial oxidative respiration, rejuvenated muscle function in aged mice. |
| 别名 | Compound IA-47 (Br- base 2246625-81-8) |
| 分子量 | 593.46 |
| 分子式 | C27H43Cl2IN2 |
| CAS No. | T60122 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 60 mg/mL (101.1 mM)
( < 1 mg/mL refers to the product slightly soluble or insoluble )
参考文献
剂量换算对于不同动物的给药剂量换算，您也可以参考 更多...
体内实验配液计算器请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法： 比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)， 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300， 混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。
计算器bottom
您可能有的问题的答案可以在抑制剂处理说明中找到，包括如何准备库存溶液，如何存储产品，以及基于细胞的分析和动物实验需要特别注意的问题。
Aldometanib T60122 Chromatin/Epigenetic Others PI3K/Akt/mTOR signaling AMPK CompoundIA47 Compound IA-47 (Br- base 2246625-81-8) Inhibitor inhibitor inhibit
沪公网安备 31010602006700号
